Wednesday, November 16, 2011 12:17:40 PM
Incyte: FDA approved Jakafi, the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis. (INCY) 12.67 +0.07 : The safety and effectiveness of Jakafi was evaluated in two clinical trials with 528 patients. Patients in both trials were resistant or refractory to available myelofibrosis therapy or ineligible for allogeneic bone marrow transplantation. All patients had enlarged spleens and were in need of treatment as a result of disease-related symptoms. The treatment is being approved ahead of the drug's Dec. 3, 2011 review goal date under the Prescription Drug User Fee Act and has been designated as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the U.S.
Recent INCY News
- Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings • Business Wire • 05/21/2024 05:15:00 PM
- Incyte to Present at Upcoming Investor Conference • Business Wire • 05/21/2024 12:00:00 PM
- Incyte präsentiert Daten aus seinem Onkologie-Portfolio beim Jahrestreffen 2024 der ASCO und beim EHA2024 Congress • Business Wire • 05/16/2024 01:45:00 AM
- Incyte présentera les données de son portefeuille d'oncologie lors de la réunion annuelle 2024 de l'ASCO et du congrès EHA2024 • Business Wire • 05/15/2024 03:44:00 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 05/15/2024 03:10:29 PM
- Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress • Business Wire • 05/14/2024 09:00:00 PM
- Producer Price Inflation Data May Weigh On Wall Street • IH Market News • 05/14/2024 01:05:30 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/13/2024 10:06:33 PM
- Dow Snaps Eight-Day Winning Streak After Lackluster Session • IH Market News • 05/13/2024 08:34:54 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 05/13/2024 03:19:07 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 05/13/2024 11:19:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:18:34 AM
- Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock • Business Wire • 05/13/2024 11:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/09/2024 10:40:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 10:25:46 PM
- Incyte to Present at Upcoming Investor Conference • Business Wire • 05/02/2024 12:00:00 PM
- Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs • Business Wire • 04/30/2024 11:00:00 AM
- Incyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorie • Business Wire • 04/23/2024 10:11:00 PM
- Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt • Business Wire • 04/23/2024 10:01:00 PM
- Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists • Business Wire • 04/23/2024 11:00:00 AM
- Incyte to Report First Quarter Financial Results • Business Wire • 04/11/2024 12:00:00 PM
- Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia • Business Wire • 04/01/2024 12:30:00 PM
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/29/2024 08:30:00 PM
- Incyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modérée • Business Wire • 03/11/2024 12:57:00 PM
- Incyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekannt • Business Wire • 03/11/2024 12:57:00 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM